Proteomic Analysis of Glioblastoma Multiforme
Author Information
Author(s): Collet Brigitte, Guitton Nathalie, Saïkali Stephan, Avril Tony, Pineau Charles, Hamlat Abderrahmane, Mosser Jean, Quillien Véronique
Primary Institution: Centre Régional de Lutte contre le Cancer; Rennes, France
Hypothesis
Can differential proteomic techniques identify new therapeutic targets and biomarkers in glioblastoma multiforme?
Conclusion
The study confirmed the importance of known proteins in glioma pathology and identified new potential targets for future therapies.
Supporting Evidence
- 51 protein spots were significantly up-regulated in GBM samples.
- Mass spectrometry identified 22 proteins from the up-regulated spots.
- Western blotting validated the differential expression of selected proteins.
Takeaway
Researchers looked at brain tumor samples to find proteins that could help treat glioblastoma, a type of brain cancer. They found some proteins that are already known to be important and discovered new ones that could help in future treatments.
Methodology
The study used 2D-DIGE and mass spectrometry to analyze protein expression in glioblastoma and non-tumorous brain samples.
Potential Biases
Potential bias in sample selection and analysis methods.
Limitations
The study focused on a limited number of samples and may not represent all glioblastoma cases.
Participant Demographics
66 patients with newly diagnosed, untreated primary glioblastoma, including 7 giant cell glioblastoma cases.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website